Premium
What are the current possibilities in treating peptic ulcer disease?
Author(s) -
DAMMANN H. G.,
WALTER TH. A.,
DREYER M.,
DAU B.,
MÜLLER P.,
SIMON B.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00657.x
Subject(s) - sucralfate , medicine , pepsin , histamine , pharmacology , gastroenterology , peptic ulcer , gastric mucosa , stomach , chemistry , biochemistry , enzyme
SUMMARY There are two major principles of ulcer therapy. Today, the most widely accepted drugs are those which substantially reduce aggressive factors (i.e. acid and pepsin), namely histamine H 2 ‐receptor antagonists, antimuscarinics and antacids. Less frequently applied are mucoprotective agents like colloidal bismuth compounds and sucralfate. Prostaglandins both reduce acid secretion substantially and are believed to enhance mucosal resistance. Their anti‐ulcer efficacy, however, is solely explicable by their antisecretory activity. Although mucosa‐strengthening agents and H 2 ‐receptor blockers have nearly identical healing rates, mucosa‐strengthening agents have inconvenient dosage regimens (four times or twice daily) and are probably less effective in relieving pain. The same holds true for antacids. Prostaglandins, antimuscarinics and antacids have dose related side effects. In contrast, H 2 ‐receptor blockers are characterized by a clear mechanism of action, convenient dosage regimes, good tolerance and a low incidence of side‐effects. H 2 ‐receptor antagonists are the most effective anti‐ulcer drugs presently available.